Efficacy and Safety of AJU-C52 in Essential Hypertension Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Efficacy and Safety of AJU-C52 in Essential Hypertension Patients — Stella

Home/Essential Hypertension/

View on ClinicalTrials.gov

Recruiting

Back to Essential Hypertension trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

South Korea

AJU Pharm Co., Ltd., Seoul

Key details

Phase

Large-scale testing

Sponsor

AJU Pharm Co., Ltd.

Enrollment target

~190 participants

Started

June 2022

Primary completion

December 2022

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

19 Years and older

Last updated May 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.